Benefits
Cognitive performance in postmenopausal women
Veri-te resveratrol at 75 mg twice daily (150 mg/day) over a year improves cognitive performance and reduces decline in brain blood vessel responsiveness in older postmenopausal women. This is a long-duration trial in a high-priority healthspan population — most resveratrol research has been short or in different demographics. Reasonable consideration for postmenopausal women interested in cognitive aging support, particularly with estrogen-decline-related symptoms.
Bone density improvement in postmenopausal women
Over the longer term, Veri-te resveratrol produces measurable increases in bone density at the lumbar spine and femoral neck in postmenopausal women, with corresponding reductions in bone resorption markers. Effect is strongest in those with active bone loss at baseline. Reasonable adjunct for postmenopausal bone health. Magnitude is smaller than bisphosphonates; not a substitute for prescription osteoporosis therapy in high-risk patients.
Bone density in obese men — replicated effect
Bone density improvements seen in postmenopausal women are also seen in obese men taking resveratrol — a different population with different baseline hormonal profiles. This replication supports the bone metabolism mechanism extending beyond purely estrogen-related pathways. Most relevant for men with metabolic syndrome or obesity-related bone health concerns.
Pain, menopausal symptoms, and quality of life
Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women. These quality-of-life endpoints matter in a population where pharmacological options are limited and HRT carries cardiovascular and cancer risks. Reasonable component of comprehensive menopausal symptom management, particularly for women preferring botanical interventions or who have HRT contraindications.
Modest blood pressure reduction
In overweight and obese hypertensive adults, resveratrol produces modest blood pressure improvements consistent with effects on blood vessel function. Effect size is small compared to antihypertensive medications. Reasonable as part of a broader cardiovascular and metabolic strategy in metabolic syndrome contexts; not validated as a standalone hypertension intervention.
Pharmaceutical-grade purity and safety
Veri-te is over 98% pure trans-resveratrol made by yeast fermentation rather than knotweed extraction. Practical implications: contains NO emodin (the laxative compound found in knotweed-derived resveratrol), more consistent batch-to-batch potency, and isn't dependent on wild knotweed harvesting. Most appropriate when consistency and purity matter — research applications and people with sensitive GI systems benefit most from the cleaner manufacturing.
Endothelial function in postmenopausal women
The cerebrovascular responsiveness improvements seen in long-term trials reflect a broader endothelial function benefit that likely underlies both the cognitive and cardiovascular effects. Healthier blood vessel responsiveness translates into better tissue perfusion across multiple organ systems. Most relevant for postmenopausal women managing the cardiovascular consequences of declining estrogen, where vascular function tends to deteriorate.
Mechanism of action
SIRT1 activation (longevity pathway)
Resveratrol activates sirtuin 1 (SIRT1) — the central NAD-dependent deacetylase implicated in caloric restriction mimicry and longevity pathways. Foundational mechanism rationale for the healthspan applications.
AMPK activation
AMP-activated protein kinase activation — energy-sensing pathway shared with metformin and exercise. Mechanistic complement to SIRT1 in the metabolic and longevity framework.
Endothelial NO production enhancement
Endothelial nitric oxide production enhancement underlies both the cardiovascular benefits and the cerebrovascular responsiveness improvements documented in RESHAW.
Estrogen receptor modulation
Mild phytoestrogenic activity via estrogen receptor binding — explains the menopausal symptom benefits and bone effects in postmenopausal women. Pregnancy avoidance recommendation reflects this mechanism.
Bone metabolism modulation
Reduces bone resorption markers (CTX-I) and increases bone alkaline phosphatase. Multi-target bone metabolism effect supporting the BMD outcomes in RESHAW and Ornstrup 2014.
NF-κB anti-inflammatory pathway suppression
NF-κB pathway suppression contributes to the broader anti-inflammatory and metabolic effects.
Antioxidant + mitochondrial biogenesis
Antioxidant activity plus mitochondrial biogenesis via PGC-1α — supports the longevity and metabolic mechanisms.
Clinical trials
RESHAW (Resveratrol Supporting Healthy Ageing in Women) Trial — University of Newcastle, Australia.
129 postmenopausal women aged 45-85
RESHAW (Resveratrol Supporting Healthy Ageing in Women) Trial — University of Newcastle, Australia. 12-month phase 1 in 129 postmenopausal women aged 45-85 at 75 mg twice daily (150 mg/day). Improved cognitive performance and reduced decline in cerebrovascular responsiveness. Pivotal long-duration clinical trial supporting cognitive aging adjunct positioning.
24-month crossover bone arm (n=125).
Clinical population described in trial publication.
24-month crossover bone arm (n=125). Improved bone density in lumbar spine and femoral neck. 7.2% reduction in plasma CTX-I bone resorption marker. Subgroup-dependent: higher baseline bone resorption benefited more. Final publication (J North American Menopause Society): improved pain, menopausal symptoms, well-being.
Clinical evidence on Veri-te™ Resveratrol (Evolva) for the indications and outcomes described.
Clinical population described in trial publication.
Ornstrup MJ et al. 2014 (J Clin Endocrinol Metab). Bone mineral density trial in obese men. Replicates RESHAW bone effects in a different population, supporting bone metabolism mechanism beyond estrogen-related pathways.